Oorsprong van het eerstegraads netwerk van Ken Smith
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Marengo Therapeutics, Inc.
 Marengo Therapeutics, Inc. BiotechnologyHealth Technology Marengo Therapeutics, Inc. operates as a biotechnology company that develops immunotherapies. Its product is Universal Targeted Immunotherapy a drug discovery platform that underpins an immunological tumor elimination. The company was founded by Andreas Loew and is headquartered in Cambridge, MA.
11
| Holding Company | Biotechnology | 11 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Ken Smith via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| CELGENE | Biotechnology | Chief Tech/Sci/R&D Officer | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| BIO-TECHNE CORPORATION | Biotechnology | Director/Board Member | |
| MERCK KGAA | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| AILERON THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Founder | |
PharmAkea, Inc.
 PharmAkea, Inc. Pharmaceuticals: MajorHealth Technology PharmAkea, Inc. develops small molecule drug candidates against protein targets involved in fibro proliferative diseases. It discovers and develops small molecule therapeutics directed at cancer and fibrotic diseases. The company was founded by John Howard Hutchinson, Kevin Holme, and Jilly Evans in 2012 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member | |
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Biotechnology | Director/Board Member Director/Board Member | |
| University of Oxford | College/University | Doctorate Degree Undergraduate Degree | |
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
Rothschild, Inc.
 Rothschild, Inc. Investment ManagersFinance Part of Rothschild & Co. The company is based in New York, NY. Continuation Holdings AG, Rothschild, Inc. provides investment banking and advisory services. | Investment Managers | Corporate Officer/Principal | |
| University of Leeds | College/University | Doctorate Degree | |
| Yale University | College/University | Graduate Degree | |
GlaxoSmithKline, Inc.
 GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| University of Toronto | College/University | Masters Business Admin | |
| Moscow State University Lomonosov | College/University | Graduate Degree | |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Dresden University of Technology | College/University | Doctorate Degree | |
| Manchester Metropolitan University | College/University | Undergraduate Degree | |
Apple Tree venture Managemnet Llc//vc
 Apple Tree venture Managemnet Llc//vc Investment ManagersFinance Apple Tree venture Managemnet LLC (Apple Tree Partners) is a venture capital firm founded by Seth Harrison in 1999. The firm is headquartered in New York with an additional offices in London, San Francisco and Cambridge. | Investment Managers | Founder Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor | |
| The Royal College of Physicians | College/University | Corporate Officer/Principal | |
| KARYOPHARM THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member | |
| AVALO THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Braeburn Pharmaceuticals SPRL
 Braeburn Pharmaceuticals SPRL Medical SpecialtiesHealth Technology Braeburn Pharmaceuticals SPRL develops and commercializes medical products. It’s a pharmaceutical company focused on novel, long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including addiction, pain, and schizophrenia. The firm offers Probuohine, CAM2038q1w, CAM2038q4w and Risperdone implant. The company was founded in 2012 and is headquartered in Road Town, British Virgin Islands. | Medical Specialties | Chairman Corporate Officer/Principal | |
Strategic Development Group, Inc.
 Strategic Development Group, Inc. Miscellaneous Commercial ServicesCommercial Services Strategic Development Group, Inc. provides site selection and consulting services. It also offers headquarter site analysis and selection; incentive analysis and negotiation; and post location follow up. The company was founded by Mark Williams and is headquartered in Columbia, SC. | Miscellaneous Commercial Services | Private Equity Investor | |
| The Leonard N Stern School of Business | College/University | Undergraduate Degree | |
| JUNO THERAPEUTICS INC | Biotechnology | Director/Board Member | |
| BRAEBURN INC. | Miscellaneous Commercial Services | Chairman Director/Board Member Private Equity Investor | |
Medicxi Ventures (Jersey) Ltd.
 Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Investment Managers | Private Equity Investor | |
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal | |
Corvidia Therapeutics, Inc.
 Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Biotechnology | Director/Board Member Director/Board Member | |
Sidecar Therapeutics, Inc.
 Sidecar Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sidecar Therapeutics, Inc. operates as a biotechnology and pharmaceutical company. It focuses on drug development for fibrotic disease. The company was founded in 2016 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member | |
Limelight Bio, Inc.
 Limelight Bio, Inc. BiotechnologyHealth Technology Limelight Bio, Inc. engages in the development of proprietary technologies, advanced targets, and drug candidates for the expansion of current gene therapy and gene editing approaches. The company was founded by Phil Johnson and Jean Bennett in 2017 and is headquartered in Philadelphia, PA. | Biotechnology | Chairman Director/Board Member | |
| AKERO THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Galvanize Therapeutics, Inc.
 Galvanize Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Galvanize Therapeutics, Inc. operates as a biotechnology firm. The company was founded in 2020 and is headquartered in Menlo Park, CA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Silagene, Inc.
 Silagene, Inc. Medical/Nursing ServicesHealth Services Silagene, Inc. provides health care services. The company is headquartered in Hillsborough, NJ. | Medical/Nursing Services | Director/Board Member | |
Ascidian Therapeutics, Inc.
 Ascidian Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascidian Therapeutics, Inc. operates as a biotechnology research and development company. The company is headquartered in Brighton, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| RAYZEBIO, INC. | Biotechnology | Founder | |
Nereid Therapeutics, Inc.
 Nereid Therapeutics, Inc. BiotechnologyHealth Technology Nereid Therapeutics, Inc. operates as a life sciences venture firm. It translates the potential of biomolecular condensates into life-changing therapeutics. The company was founded by Clifford Brangwynne and Spiros Liras and is headquartered in Cambridge, MA. | Biotechnology | Chairman Director/Board Member | |
Aulos Bioscience, Inc.
 Aulos Bioscience, Inc. BiotechnologyHealth Technology Aulos Bioscience, Inc. operates as a biotechnology firm. The company is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| CENTESSA PHARMACEUTICALS PLC | Pharmaceuticals: Major | Director/Board Member | |
Replicate Bioscience, Inc.
 Replicate Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Replicate Bioscience, Inc. is a clinical-stage biopharmaceutical company based in San Diego, CA. The company focuses on creating novel oncology treatments to prevent drug resistance using its synrgy technology. Replicate aims to enhance the effectiveness of many immuno-oncology regimens in early stages of care and is developing its own pipeline of immuno-oncology products in breast, lung, and prostate cancers. Replicate is differentiated by a team of srrna experts, a customizable library of synthetic srrna vectors, and end-to-end development capabilities. The company harnesses the body's natural protein-making power and uses synthetic biology to design unique self-replicating rnas (srrnas) that can direct that power to fight disease. The company was founded by Nathaniel Whang, Zachary Hartman, Michael D. Ehlers, Herbert Kim Lyerly, Andrew J. Geall, and Nathaniel Whang has been the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Intergalactic Therapeutics, Inc.
 Intergalactic Therapeutics, Inc. BiotechnologyHealth Technology Intergalactic Therapeutics, Inc. is a gene therapy company based in Baltimore, MD. The company is revolutionizing gene therapies with a novel non-viral platform comprised of its versatile synthetic and episomal c3dna molecules. The company uses a customized approach to focal therapeutic delivery using its lead delivery technology, the comet pulsed electric field system, and a proprietary cell-free manufacturing process invented to make gene therapy safer and more accessible for patients. With programs in ophthalmology, oncology, respiratory diseases, and expansion areas including CNS, renal, and musculoskeletal, Intergalactic Therapeutics is dedicated to transforming genetic medicine. The company was founded by Michael D. Ehlers, and Theresa G. H. Heah has been the CEO of the company since 2023. | Biotechnology | Director/Board Member Director/Board Member | |
Ceptur Therapeutics, Inc.
 Ceptur Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Ceptur Therapeutics, Inc. is a company that focuses on developing medicines for severe diseases in the areas of oncology, the central nervous system, nephrology, and immunology. The company is based in Hillsborough, NJ and has subsidiaries in the United States. The company is revolutionizing RNA therapeutics with U1 adaptor technology to address unaddressed diseases. The company was founded by Rafal Goraczniak and P. Peter Ghoroghchian, with P. Peter Ghoroghchian serving as CEO since incorporation. | Pharmaceuticals: Other | Director/Board Member | |
| Petrichor Scion Therapeutics Management LLC | Investment Managers | Founder | |
Long Covid Research Initiative
 Long Covid Research Initiative BiotechnologyHealth Technology The Long Covid Research Initiative develops comprehensive research programs. The company is based in Los Angeles, CA. The company was founded by Henry Scott-Green, Nick Harrold, Helga Gutmane, Amy Proal. | Biotechnology | Chairman | |
Tourmaline Bio, Inc.
 Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Miscellaneous Commercial Services | Director/Board Member |
Statistieken
Internationaal
| Verenigde Staten | 38 |
| Verenigd Koninkrijk | 7 |
| Duitsland | 3 |
| Canada | 3 |
| Rusland | 2 |
Sectoraal
| Health Technology | 29 |
| Consumer Services | 10 |
| Commercial Services | 7 |
| Finance | 6 |
| Health Services | 2 |
Operationeel
| Director/Board Member | 70 |
| Corporate Officer/Principal | 16 |
| Chairman | 13 |
| Independent Dir/Board Member | 12 |
| Private Equity Investor | 9 |
Sterkste connecties
| Insiders | |
|---|---|
| Seth Harrison | 43 |
| Aaron Kantoff | 19 |
| Anna Batarina | 14 |
| Joseph Yanchik | 13 |
| Rupert Vessey | 13 |
| Su Zhen | 7 |
| Andrew Bayliffe | 4 |
| Mark J Smyth | 2 |
| E. John Wherry | 2 |
| John Hastewell | 2 |
| Arlene Sharpe | 1 |
